局部晚期非小细胞肺癌同步放化疗后采用免疫治疗巩固前後的肺炎发生率
这项单机构多院区回顾性研究纳入783例接受根治性同步放化疗的局部晚期非小细胞肺癌患者,比较免疫检查点抑制剂巩固治疗引入前(448例)与引入后(335例)的症状性肺炎发生率。免疫治疗时代≥2级肺炎1年累积发生率较高(31.4% vs 20.1%,P<.001),≥3级肺炎未见升高(7.5% vs 6.0%,P=.39)。
要点
- 免疫治疗巩固引入后≥2级肺炎1年累积发生率由20.1%升至31.4%,校正后风险比为2.03。
- ≥3级肺炎在免疫治疗时代未升高(7.5% vs 6.0%,P=.39)。
- 免疫治疗时代肺V20阈值为28%,高于与低于该阈值者1年≥2级肺炎率分别为46.0%与19.8%。
核心结论
- 在接受同步放化疗的局部晚期非小细胞肺癌患者中,采用免疫检查点抑制剂巩固治疗与≥2级肺炎增加相关,但与≥3级肺炎增加无关。
- 作者认为,采用免疫检查点抑制剂巩固治疗时,可能需要更严格的肺剂量限制。
研究设计与样本
- 单机构、多院区回顾性研究,纳入783例接受根治性同步放化疗的局部晚期非小细胞肺癌患者。
- 免疫检查点抑制剂引入前队列(2011年1月至2017年9月)448例,免疫检查点抑制剂时代队列(2017年10月至2021年12月)335例。
- 主要终点为≥2级肺炎,次要终点为≥3级肺炎,依据常见不良事件评价标准第5版判定。
- 采用累积发生率函数和Gray检验比较肺炎发生率,并构建逆概率治疗加权校正的Fine-Gray模型。
- 构建逻辑回归模型,以肺剂量学参数预测1年≥2级肺炎概率。
主要发现
- 免疫检查点抑制剂时代队列≥2级肺炎1年累积发生率为31.4%,高于免疫检查点抑制剂引入前队列的20.1%(P<.001);逆概率治疗加权校正多变量亚分布风险比为2.03(95%CI 1.53-2.70,P<.001)。
- 在Fine-Gray回归中,免疫检查点抑制剂时代治疗与肺V20或平均肺剂量之间对≥2级肺炎无显著交互作用;但在临床相关肺V20(≥24%)和平均肺剂量(≥14 Gy)取值下,免疫检查点抑制剂时代≥2级肺炎预测概率较高。
- 切点分析显示,免疫检查点抑制剂时代肺V20阈值为28%,高于与低于该阈值者1年≥2级肺炎率分别为46.0%与19.8%(P<.001)。
- 在接受免疫检查点抑制剂巩固治疗的患者中,肺V5与≥2级肺炎无关。
- 免疫检查点抑制剂时代队列≥3级肺炎1年累积发生率为7.5%,免疫检查点抑制剂引入前队列为6.0%(P=.39);逆概率治疗加权校正多变量亚分布风险比为1.12(95%CI 0.63-2.01,P=.70)。
关键数值与推荐
- 免疫检查点抑制剂时代队列与免疫检查点抑制剂引入前队列≥2级肺炎1年累积发生率分别为31.4%与20.1%(P<.001)。
- 免疫检查点抑制剂时代队列与免疫检查点抑制剂引入前队列≥3级肺炎1年累积发生率分别为7.5%与6.0%(P=.39)。
- 免疫检查点抑制剂时代肺V20阈值为28%,高于与低于该阈值者1年≥2级肺炎率分别为46.0%与19.8%(P<.001)。
临床怎么用
- 作者认为,采用免疫检查点抑制剂巩固治疗时,可能需要更严格的肺剂量限制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We hypothesized that after adoption of immune checkpoint inhibitor (ICI) consolidation for patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent chemoradiation therapy (cCRT), rates of symptomatic pneumonitis would increase, thereby supporting efforts to reduce lung radiation dose. METHODS AND MATERIALS: This single institution, multisite retrospective study included 783 patients with LA-NSCLC treated with definitive cCRT either before introduction of ICI consolidation (pre-ICI era cohort [January 2011-September 2017]; N = 448) or afterward (ICI era cohort [October 2017-December 2021]; N = 335). Primary endpoint was grade ≥2 pneumonitis (G2P) and secondary endpoint was grade ≥3 pneumonitis (G3P), per Common Terminology Criteria for Adverse Events v5.0. Pneumonitis was compared between pre-ICI era and ICI era cohorts using the cumulative incidence function and Gray's test. Inverse probability of treatment weighting (IPTW)-adjusted Fine-Gray models were generated. Logistic models were developed to predict the 1-year probability of G2P as a function of lung dosimetry. RESULTS: G2P was higher in the ICI era than in the pre-ICI era (1-year cumulative incidence 31.4% vs 20.1%; P < .001; IPTW-adjusted multivariable subdistribution hazard ratio, 2.03; 95% confidence interval, 1.53-2.70; P < .001). There was no significant interaction between ICI era treatment and either lung volume receiving ≥20 Gy (V20) or mean lung dose in Fine-Gray regression for G2P; however, the predicted probability of G2P was higher in the ICI era at clinically relevant values of lung V20 (≥24%) and mean lung dose (≥14 Gy). Cut-point analysis revealed a lung V20 threshold of 28% in the ICI era (1-year G2P rate 46.0% above vs 19.8% below; P < .001). Among patients receiving ICI consolidation, lung V5 was not associated with G2P. G3P was not higher in the ICI era (1-year cumulative incidence 7.5% vs 6.0%; P = .39; IPTW-adjusted multivariable subdistribution hazard ratio, 1.12; 95% confidence interval, 0.63-2.01; P = .70). CONCLUSIONS: In patients with LA-NSCLC treated with cCRT, the adoption of ICI consolidation was associated with an increase in G2P but not G3P. With ICI consolidation, stricter lung dose constraints may be warranted.
引用
- Yegya-Raman N, Friedes C, Lee SH, et al. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation. Int J Radiat Oncol Biol Phys. 2023. PMID: 37619788. doi:10.1016/j.ijrobp.2023.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。